436 related articles for article (PubMed ID: 30741108)
1. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S
Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis.
Kalinin I; Makshakov G; Evdoshenko E
AJNR Am J Neuroradiol; 2020 May; 41(5):804-808. PubMed ID: 32381540
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
[TBL] [Abstract][Full Text] [Related]
5. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
[TBL] [Abstract][Full Text] [Related]
6. Grey matter atrophy in patients with benign multiple sclerosis.
Niiranen M; Koikkalainen J; Lötjönen J; Selander T; Cajanus A; Hartikainen P; Simula S; Vanninen R; Remes AM
Brain Behav; 2022 Jul; 12(7):e2679. PubMed ID: 35765699
[TBL] [Abstract][Full Text] [Related]
7. Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.
Noteboom S; Strijbis EMM; Coerver EME; Colato E; van Kempen ZLE; Jasperse B; Vrenken H; Killestein J; Schoonheim MM; Steenwijk MD
Mult Scler Relat Disord; 2024 Jul; 87():105670. PubMed ID: 38772150
[TBL] [Abstract][Full Text] [Related]
8. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
[TBL] [Abstract][Full Text] [Related]
9. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
Nakamura K; Sun Z; Hara-Cleaver C; Bodhinathan K; Avila RL
Mult Scler; 2024 May; 30(6):687-695. PubMed ID: 38469809
[TBL] [Abstract][Full Text] [Related]
11. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
[TBL] [Abstract][Full Text] [Related]
12. Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI.
Parra Corral MA; Govindarajan ST; Stefancin P; Bangiyev L; Coyle PK; Duong TQ
Mult Scler Relat Disord; 2019 Jun; 31():74-81. PubMed ID: 30951968
[TBL] [Abstract][Full Text] [Related]
13. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
[TBL] [Abstract][Full Text] [Related]
14. Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis.
Jakimovski D; Zivadinov R; Bergsland N; Ramasamy DP; Hagemeier J; Weinstock-Guttman B; Kolb C; Hojnacki D; Dwyer MG
J Neuroimaging; 2020 May; 30(3):342-350. PubMed ID: 32392376
[TBL] [Abstract][Full Text] [Related]
15. Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment.
Uher T; Benedict RH; Horakova D; Bergsland N; Dusankova JB; Tyblova M; Ramasamy DP; Seidl Z; Vaneckova M; Krasensky J; Havrdova E; Zivadinov R
J Neurol Sci; 2014 Dec; 347(1-2):229-34. PubMed ID: 25456460
[TBL] [Abstract][Full Text] [Related]
16. Detection of Cortical and Deep Gray Matter Lesions in Multiple Sclerosis Using DIR and FLAIR at 3T.
Park CC; Thongkham DW; Sadigh G; Saindane AM; Chu R; Bakshi R; Allen JW; Hu R
J Neuroimaging; 2021 Mar; 31(2):408-414. PubMed ID: 33351983
[TBL] [Abstract][Full Text] [Related]
17. New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
Sinnecker T; Ruberte E; Schädelin S; Canova V; Amann M; Naegelin Y; Penner IK; Müller J; Kuhle J; Décard B; Derfuss T; Kappos L; Granziera C; Wuerfel J; Magon S; Yaldizli Ö
J Neurol; 2020 Jan; 267(1):192-202. PubMed ID: 31612322
[TBL] [Abstract][Full Text] [Related]
18. Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy.
Engl C; Tiemann L; Grahl S; Bussas M; Schmidt P; Pongratz V; Berthele A; Beer A; Gaser C; Kirschke JS; Zimmer C; Hemmer B; Mühlau M
J Neurol; 2020 Aug; 267(8):2307-2318. PubMed ID: 32328718
[TBL] [Abstract][Full Text] [Related]
19. Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability.
Chu R; Hurwitz S; Tauhid S; Bakshi R
BMC Neurol; 2017 Sep; 17(1):172. PubMed ID: 28874119
[TBL] [Abstract][Full Text] [Related]
20. Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
Lee H; Nakamura K; Narayanan S; Brown R; Chen J; Atkins HL; Freedman MS; Arnold DL
Mult Scler; 2018 Jul; 24(8):1055-1066. PubMed ID: 28617152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
